Results 171 to 180 of about 58,205 (308)

Evaluation of the rapid Idylla IDH1-2 mutation assay in FFPE glioma samples

Diagnostic Pathology
IDH1 and IDH2 mutational status is a critical biomarker with diagnostic, prognostic, and treatment implications in glioma. Although IDH1 p.R132H-specific immunohistochemistry is available, it is unable to identify other mutations in IDH1/2.
James P. Solomon, Carlos Munoz-Zuluaga, Cheyanne Slocum, Alicia Dillard, Lin Cong, Jiajing Wang, Neal Lindeman, Michael Kluk, Benjamin Liechty, David Pisapia, Hanna Rennert, Priya D. Velu   +11 more
doaj   +1 more source

Figure S3 from A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model [PDF]

, 2023
Yukino Machida, Makoto Nakagawa, Hironori Matsunaga, Masayuki Yamaguchi, Yoko Ogawara, Yutaka Shima, Kazutsune Yamagata, Takuo Katsumoto, Ayuna Hattori, Masato Itoh, Takahiko Seki, Yumi Nishiya, Kōichi Nakamura, Kanae Suzuki, Tomoki Imaoka, Daichi Baba, Makoto Suzuki, Oltea Sampetrean, Hideyuki Saya, Koichi Ichimura, Issay Kitabayashi   +20 more
openalex   +1 more source

IDH1 Protein Variant [PDF]

, 2020
openaire   +1 more source

Metabolism‐Regulating Nanomedicines for Cancer Therapy

Advanced NanoBiomed Research, Volume 6, Issue 1, January 2026.
This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley   +1 more source

Supplementary figure-2 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma

, 2023
Joydeep Mukherjee, Tor‐Christian Johannessen, Shigeo Ohba, Tracy T. Chow, Lindsey Jones, Ajay Pandita, Russell O. Pieper   +6 more
openalex   +1 more source

IDH1 Gene Mutation [PDF]

, 2020
openaire   +1 more source

Nanobiotechnology‐Based Approaches for Targeted Glioma Therapy

Advanced NanoBiomed Research, Volume 6, Issue 1, January 2026.
Nanoparticle systems cross the blood–brain barrier to deliver drugs precisely to glioma cells. Lipid, polymeric, and magnetic carriers enable controlled release, tumor targeting, and microenvironment modulation. These nanoplatforms enhance chemotherapy, radiotherapy, and immunotherapy, improving therapeutic efficacy while reducing systemic toxicity ...
Jinwei Li, Yibo He, Yang Zhang, Lining Arnold Ju, Yao Wang, Jianxuan Zhou, Yinying Chai, Xuhui Hui, ShiYuan Tong, Si Zhang, Yanli Tan, Yinyan Wang   +11 more
wiley   +1 more source

Supplementary Figures 1 - 6 from IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism

, 2023
Alexandra Grassian, Seth J. Parker, Shawn M. Davidson, Ajit S. Divakaruni, Courtney R. Green, Xiamei Zhang, Kelly L. Slocum, Minying Pu, Fallon Lin, Chad Vickers, Carol Joud-Caldwell, Franklin Chung, Hong Yin, Erika D. Handly, Christopher Straub, Joseph D. Growney, Matthew G. Vander Heiden, Anne N. Murphy, Raymond Pagliarini, Christian M. Metallo   +19 more
openalex   +1 more source

IDH1 NP_005887.2:p.R119Q [PDF]

, 2020
openaire   +1 more source

The Mutation Patterns of MET Gene in Lung Cancer and Brain Tumors: Clinical and Therapeutic Implications

Cancer Medicine, Volume 15, Issue 1, January 2026.
ABSTRACT Objectives MET aberrations are capable of triggering oncogenesis through multiple clinical significance genomic alterations. In non‐small cell lung cancer, MET exon 14 skipping and MET amplification confer sensitivity to MET tyrosine kinase inhibitors. The MET gene is also one of the druggable genes in high‐grade gliomas. However, a systematic
Yu Zhang, Ningning Luo, Minghui Ge, Yanxiang Zhang, Dongsheng Chen, Yongmeng Li   +5 more
wiley   +1 more source